Still, XLV is in superior technical shape relative to IBB although the former devotes over 18% of its weight to the biotech industry. XLV is 6.5% above its 200-day moving average and just 3.6% below its 52-week high.
Just four of the 30 members of the Dow Jones Industrial Average are up at least 10% year-to-date, but two – Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) – combine for over 20% of XLV’s weight. [Health Care ETF Looks for Lost Glory]
iShares Nasdaq Biotechnology ETF
ETF Trends editorial team contributed to this post.